SCHEMBL1720162

SCHEMBL1720162

C/C(=C/C(=O)c1ccc(F)cc1)NC(Cc1ccc(OCCc2cccc3c2[nH]c2ccccc23)cc1)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARG P37231 19/20 0.57
PPARA Q07869 1/20 0.54
ITGB3 P05106 1/20 0.44
ITGB1 P05556 1/20 0.44
ITGAV P06756 1/20 0.44
ITGA5 P08648 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720166 1.00 PPARG (0.57) PPARGPPARAITGB3ITGB1ITGAV
SCHEMBL1720631 0.95 PPARG (0.63) PPARGPPARAITGB3ITGB1ITGAV
SCHEMBL1720625 0.95 PPARG (0.63) PPARGPPARAITGB3ITGB1ITGAV
SCHEMBL1719751 0.89 PPARG (0.55) PPARGPPARAITGB3ITGB1ITGAV
SCHEMBL1719745 0.89 PPARG (0.55) PPARGPPARAITGB3ITGB1ITGAV
SCHEMBL1720165 0.87 PPARG (0.59) PPARGPPARA
SCHEMBL1720628 0.82 PPARG (0.65) PPARGPPARAITGB3ITGB1ITGAV
SCHEMBL1720328 0.82 PPARG (0.64) PPARGPPARA
SCHEMBL29930321 0.82 PPARG (0.64) PPARGPPARA
SCHEMBL29930451 0.81 PPARG (0.63) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569904-B1 SUBSTITUTED ARYLALCANOIC ACID DERIVATIVES AS PPAR PAN AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES LTD (CN) 2012-01-11 EP disclosed
US-20080051321-A1 Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity LU XIAN-PING 2008-02-28 US disclosed
US-7268157-B2 Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity SHENZHEN CHIPSCREEN BIOSCIENCES, LTD. (CN) 2007-09-11 US disclosed
US-20040142921-A1 Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142921-A1 Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity GPR119, PPARG, PPARA PPARG 2/4885PPARA 3/4885ITGB3 1819/4885
US-20080051321-A1 Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity GPR119, PPARG, PPARA PPARG 2/4885PPARA 3/4885ITGB3 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.